| Dr Daniel Goltz, DO | |
|
600 N Wolfe St, Baltimore, MD 21264-7791 | |
| (410) 955-5080 | |
| Not Available |
| Full Name | Dr Daniel Goltz |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013321769 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 25MB10444000 (New Jersey) | Secondary |
| 207P00000X | Emergency Medicine | DO210012330 (District Of Columbia) | Primary |
| Entity Name | Coney Island Medical Practice Plan, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386951762 PECOS PAC ID: 5496944803 Enrollment ID: O20110114000660 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.
Watch out - you may learn something and not even know it, says Takeo Watanabe, an associate professor of psychology at Boston University's Center for Brain and Memory. Watanabe and his team recently pinpointed the mechanism that makes subliminal learning work. Watanabe will present the team's findings at the American Psychological Society meeting in Los Angeles, May 27 and 28.
Administration officials are increasingly courting key stakeholders on health care. The New York Times reports: "After months of cutting deals and stroking drug makers, hospitals and doctors, the president's aides are laying the groundwork for a final round of Congressional arm-twisting. ... One Democrat who consults frequently with the White House said that a main goal of the administration has been to prevent any Democrat from publicly declaring opposition to the measure."
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
It's common to associate cannabis use with affluent youth in wealthy societies. But the relationship between societal and family affluence and cannabis use appears to be changing.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Goltz, DO 6201 Greenleigh Ave, Baltimore, MD 21220-2004 Ph: (410) 933-6340 | Dr Daniel Goltz, DO 600 N Wolfe St, Baltimore, MD 21264-7791 Ph: (410) 955-5080 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.
Watch out - you may learn something and not even know it, says Takeo Watanabe, an associate professor of psychology at Boston University's Center for Brain and Memory. Watanabe and his team recently pinpointed the mechanism that makes subliminal learning work. Watanabe will present the team's findings at the American Psychological Society meeting in Los Angeles, May 27 and 28.
Administration officials are increasingly courting key stakeholders on health care. The New York Times reports: "After months of cutting deals and stroking drug makers, hospitals and doctors, the president's aides are laying the groundwork for a final round of Congressional arm-twisting. ... One Democrat who consults frequently with the White House said that a main goal of the administration has been to prevent any Democrat from publicly declaring opposition to the measure."
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
It's common to associate cannabis use with affluent youth in wealthy societies. But the relationship between societal and family affluence and cannabis use appears to be changing.
› Verified 7 days ago
Ankita Taneja, MD, MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2079 | |
Scott Mcpherson, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 301 Saint Paul Pl, Baltimore, MD 21202 Phone: 410-332-9809 | |
Larry Weiss, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-4383 | |
Shannon Brandy Putman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-2280 | |
Arjun S Chanmugam, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-2280 | |
Dr. Donald W Alves, MD, MS, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1201 Reisterstown Road, Medical Services, Baltimore, MD 21208 Phone: 410-653-8366 Fax: 410-653-4290 | |
Michael Rayner Leedom, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Emergency Dept, Baltimore, MD 21201 Phone: 410-328-8025 Fax: 410-328-8028 |